ID27487A - Komposisi farmasi yang mengandung penghambat fosfolipase natrium (3-(2-amino-1,2-dioksoetil)-2-etil-1-fenilmetil) 1h-indol-4) oksi) asetat - Google Patents

Komposisi farmasi yang mengandung penghambat fosfolipase natrium (3-(2-amino-1,2-dioksoetil)-2-etil-1-fenilmetil) 1h-indol-4) oksi) asetat

Info

Publication number
ID27487A
ID27487A IDW20001981A ID20001981A ID27487A ID 27487 A ID27487 A ID 27487A ID W20001981 A IDW20001981 A ID W20001981A ID 20001981 A ID20001981 A ID 20001981A ID 27487 A ID27487 A ID 27487A
Authority
ID
Indonesia
Prior art keywords
dioxoethyl
phenylmethyl
indol
acetate
ethyl
Prior art date
Application number
IDW20001981A
Other languages
English (en)
Indonesian (id)
Inventor
William L Confer
Hideaki Tai
Original Assignee
Shionolog & Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionolog & Co Ltd filed Critical Shionolog & Co Ltd
Publication of ID27487A publication Critical patent/ID27487A/id

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IDW20001981A 1998-03-03 1999-03-02 Komposisi farmasi yang mengandung penghambat fosfolipase natrium (3-(2-amino-1,2-dioksoetil)-2-etil-1-fenilmetil) 1h-indol-4) oksi) asetat ID27487A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7665998P 1998-03-03 1998-03-03

Publications (1)

Publication Number Publication Date
ID27487A true ID27487A (id) 2001-04-12

Family

ID=22133426

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20001981A ID27487A (id) 1998-03-03 1999-03-02 Komposisi farmasi yang mengandung penghambat fosfolipase natrium (3-(2-amino-1,2-dioksoetil)-2-etil-1-fenilmetil) 1h-indol-4) oksi) asetat

Country Status (21)

Country Link
US (1) US6166062A (ja)
EP (1) EP1058547B1 (ja)
JP (3) JP2002505282A (ja)
KR (1) KR20010034552A (ja)
CN (1) CN1299277A (ja)
AT (1) ATE310513T1 (ja)
AU (1) AU757002B2 (ja)
BR (1) BR9908479A (ja)
CA (1) CA2322796A1 (ja)
DE (1) DE69928500T2 (ja)
EA (1) EA003864B1 (ja)
ES (1) ES2253877T3 (ja)
HU (1) HUP0102812A3 (ja)
ID (1) ID27487A (ja)
IL (1) IL138154A0 (ja)
NO (1) NO20004306L (ja)
NZ (1) NZ506578A (ja)
PL (1) PL342822A1 (ja)
TR (1) TR200002543T2 (ja)
TW (1) TW570795B (ja)
WO (1) WO1999044604A1 (ja)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001236440A1 (en) * 2000-01-25 2001-08-07 Eli Lilly And Company Method for the treatment of inflammation with spla2 inhibitors
AU2001229252A1 (en) * 2000-03-09 2001-09-17 Eli Lilly And Company Method for the treatment of renal dysfunction with spla2 inhibitors
WO2002005796A2 (en) * 2000-07-14 2002-01-24 Eli Lilly And Company Use of a spla2 inhibitor for the treatment of sepsis
TWI232102B (en) * 2001-07-17 2005-05-11 Shionogi & Co A pharmaceutical formulation for injection
CN1568999A (zh) * 2003-07-14 2005-01-26 南宁枫叶药业有限公司 稳定的医药用河豚毒素冷冻干燥制剂
US20050250738A1 (en) * 2004-05-06 2005-11-10 Mosher Gerold L Taste-masked formulations containing sertraline and sulfoalkyl ether cyclodextrin
TWI397409B (zh) * 2006-06-09 2013-06-01 Sanol Arznei Schwarz Gmbh 含菲索特羅定之安定化醫藥組成物
SI2111124T1 (sl) * 2007-02-12 2012-03-30 Lassaad Boujbel Sterilna raztopina sukraloze brez konzervansov inpostopek priprave le te
JP5174365B2 (ja) * 2007-03-23 2013-04-03 第一三共株式会社 キノロン含有凍結乾燥製剤の製造方法
EP2106788A1 (en) * 2008-04-04 2009-10-07 Ipsen Pharma Liquid and freeze dried formulations
EP3791880A1 (en) 2009-04-29 2021-03-17 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising epa
US20140179633A1 (en) * 2011-08-26 2014-06-26 Jw Pharmaceutical Corporation Composition comprising pyrazino-triazine derivatives
EP2923710A1 (en) 2014-03-27 2015-09-30 Universitätsklinikum Heidelberg Bacterial phospholipase inhibitors as modulator of colonic bacterial flora

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO873860L (no) * 1986-10-31 1988-05-02 Asta Pharma Ag Ifosfamid-lyofilisat og fremgangsmaate til deres fremstilling.
JPH02207092A (ja) * 1989-02-07 1990-08-16 Kirin Brewery Co Ltd アンスラサイクリン化合物またはその塩の凍結乾燥製剤の製造法
WO1995011683A1 (en) * 1993-10-27 1995-05-04 The Upjohn Company Stabilized prostaglandin e¿1?
DK1950200T3 (da) * 1994-04-01 2012-04-10 Lilly Co Eli [[3-(2-AMINO-1,2-DIOXOETHYL)-2-ETHYL-1-(PHENYLMETHYL)-11H-INDOL-4-YL]OXY]EDDIKESYREMETHYLESTER SOM sPLA2-INHIBITOR

Also Published As

Publication number Publication date
EP1058547A1 (en) 2000-12-13
CA2322796A1 (en) 1999-09-10
NZ506578A (en) 2003-09-26
EA200000897A1 (ru) 2001-02-26
JP2002505282A (ja) 2002-02-19
WO1999044604A9 (en) 2000-01-20
NO20004306L (no) 2000-10-10
EP1058547B1 (en) 2005-11-23
WO1999044604A1 (en) 1999-09-10
AU2799899A (en) 1999-09-20
PL342822A1 (en) 2001-07-02
NO20004306D0 (no) 2000-08-29
ATE310513T1 (de) 2005-12-15
HUP0102812A2 (hu) 2001-12-28
US6166062A (en) 2000-12-26
DE69928500T2 (de) 2006-08-03
JP2011021042A (ja) 2011-02-03
HUP0102812A3 (en) 2002-01-28
IL138154A0 (en) 2001-10-31
EA003864B1 (ru) 2003-10-30
BR9908479A (pt) 2000-12-05
TR200002543T2 (tr) 2000-11-21
AU757002B2 (en) 2003-01-30
KR20010034552A (ko) 2001-04-25
DE69928500D1 (de) 2005-12-29
CN1299277A (zh) 2001-06-13
ES2253877T3 (es) 2006-06-01
JP2006096761A (ja) 2006-04-13
TW570795B (en) 2004-01-11

Similar Documents

Publication Publication Date Title
ID27487A (id) Komposisi farmasi yang mengandung penghambat fosfolipase natrium (3-(2-amino-1,2-dioksoetil)-2-etil-1-fenilmetil) 1h-indol-4) oksi) asetat
ES2155043B1 (es) Composiciones farmaceuticas comprendiendo acido pirimidin-5-il(3r, 5s)-3,5-dihidroxihept-6-enoico o una sal suya, su estabilizacion con sal fosfato tribasico y su preparacion.
EA200000433A1 (ru) Комбинация ингибитора альдозоредуктазы и ингибитора гликогенфосфорилазы
EA200000871A1 (ru) Ингибиторы фосфолипазных ферментов
BR0014486A (pt) Composições farmacêuticas contendo polipeptìdeo lìquido estabilizado
BR0016555A (pt) Composições farmacêuticas que proporcionam concentrações acrescidas de droga
HUP0300850A2 (hu) Gyűrűs béta-aminosav-származékok mint mátrix metalloproteázok és a TNF-alfa inhibitorok és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
IL208697A0 (en) Aqueous based pharmaceutical formulations of water-soluble prodrugs of propofol
ATE404176T1 (de) Stabilisierte lyophilisierte zubereitungen mit gewebefaktor-inhibitor (tfpi) oder varianten des gewebefaktor-inhibitors
DK0722313T3 (da) Viskoelastiske sammensætninger af fluorerede organiske forbindelser
TR199802394A2 (xx) Proteinleri stabilize etmek i�in geli�tirilmi� proses.
GEP20115348B (en) Pharmaceutical composition for treating burns (variants) and methods for the production thereof (variants)
AR006523A1 (es) Compuestos ciclicos, inhibidores de la adhesion
BRPI0407652A (pt) método para acentuar a eficácia de um agente ativo, composição e método para produzir a composição
TR200201103T2 (tr) İkame edilmiş benzimidazol formülasyonları
JP2945923B2 (ja) 養毛剤
PT769951E (pt) Composicao de oxitetraciclina de longa accao
TR200100611T2 (tr) İbuprofen ve domperidon içeren farmasötik kompozisyonlar
BR0109139B1 (pt) composiÇÕes farmacÊuticas incluindo alginatos
BR9803730A (pt) Preparados farmacêuticos de cilansetron estabilizados contra a racemização.
DE69819900D1 (de) Wässrige flüssige pharmazeutische zusammensetzung enthaltend ein benzopyranderivat als hauptbestandteil
ATE348621T1 (de) Flüssige darreichungsformen oxazaphosphorinhaltiger pharmazeutischer produkte
ID21755A (id) Antijamur azol yang mengandung ester asam amino
EA200900249A1 (ru) Фармацевтическая композиция и способ ее получения
TR200003570T2 (tr) Mumbaistatin, Üretim yöntemi ve farmasötik kullanımı